Top 3 Health Care Stocks That May Rocket Higher In September

Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider

The global intravenous immunoglobulin (IVIG) market is projected to grow from USD 14.98 billion in 2025 to USD 30.83 billion by 2035, at a CAGR of 7.49%. Growth is driven by expanding neurological indications, increased plasma collection capacity, and rising demand for immunoglobulin-based treatments. However, plasma supply dependency and a 100% U.S. tariff on imported IVIG products implemented in October 2025 pose significant constraints. North America leads the market, while Asia-Pacific shows the fastest growth.

Shares of medical device-related companies are trading lower amid possible sympathy with Boston Scientific after that company announced it was likely to miss its FY26 and Q3 adjusted EPS and net sales growth guidance following a previously announced cybersecurity incident that affected operations.

Drug Reconstitution Systems Market Trends, Shares and Growth Opportunities Worldwide 2026-2035 Featuring Profiles of Baxter, ICU Medical, B. Braun, Vetter Pharma, Nipro, SCHOTT-KAISHA

The global drug reconstitution systems market is expected to grow at a 7.0% CAGR from $5.9 billion in 2026 to $10.8 billion by 2035, driven by expanding biologic and biosimilar pipelines, increasing demand for safer drug delivery systems, and the shift toward home healthcare and self-administered therapies. Cartridges lead the market at 50% revenue share, while prefilled syringes are expected to grow faster. Asia-Pacific is projected to achieve the fastest regional growth.

CVS Health's Aetna Reduces Administrative Tasks For Cancer Care

CVS unit Aetna expands prior authorization bundles to accelerate cancer care and reduce administrative burdens for healthcare providers.

BTSG Faces $200M IRA Hit but Efficiency May Protect Profitability

BrightSpring Health Services' Home and Community Pharmacy segment experienced an 8% revenue decline to $540M in Q2, with the Inflation Reduction Act (IRA) accounting for approximately $50M of the impact. Despite a projected $200M revenue headwind in 2026 from IRA pricing changes, the company expects only a $15M EBITDA impact, demonstrating that operational efficiency gains from technology, automation, AI, and Lean initiatives are offsetting regulatory pressures. Peer companies Cardinal Health and CVS Health are similarly navigating IRA-driven revenue pressures while maintaining profitability through service agreements and operational improvements.

CVS Health Unit Aetna Announces Expansion Of Prior Authorization Bundles Across All Cancer Types For Members In Eligible Medicaid States As Of September 1, With Plans To Expand Across All Lines Of Business In 2027

This expansion builds on the success of the initial roll-out, with almost 25% of eligible members receiving a bundled prior authorization, assuring their services have been approved in advance to accelerate their access